{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:08:28Z","timestamp":1767182908443,"version":"build-2238731810"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0212460","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T13:43:45Z","timestamp":1550151825000},"page":"e0212460","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-6761","authenticated-orcid":true,"given":"Guttorm","family":"Raknes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-3368","authenticated-orcid":true,"given":"Lars","family":"Sm\u00e5brekke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.intimp.2018.05.020","article-title":"Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy","volume":"61","author":"Z Li","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.brainres.2011.01.036","article-title":"Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis","volume":"1381","author":"KA Rahn","year":"2011","journal-title":"Brain Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12865-015-0093-0","article-title":"Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis","volume":"16","author":"PJ McLaughlin","year":"2015","journal-title":"BMC Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial","volume":"56","author":"JP Smith","year":"2011","journal-title":"Dig Dis Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"BA Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jdcr.2018.06.001","article-title":"Treatment of psoriasis vulgaris using low-dose naltrexone","volume":"4","author":"AC Bridgman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"ref7","unstructured":"Skard K. Unknown medicine LDN gives hope to thousands of patients. Tv2.no. 8 May 2013. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.tv2.no\/a\/5316228\" xlink:type=\"simple\">http:\/\/www.tv2.no\/a\/5316228<\/ext-link>. Cited 23 November 2018."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/pds.4110","article-title":"A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study","volume":"26","author":"G Raknes","year":"2017","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e0187423","DOI":"10.1371\/journal.pone.0187423","article-title":"Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study","volume":"12","author":"G Raknes","year":"2017","journal-title":"PLoSONE"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ecco-jcc\/jjy008","article-title":"The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study","volume":"12","author":"G Raknes","year":"2018","journal-title":"J Crohns Colitis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/pds.4201","article-title":"Low dose naltrexone and opioid consumption. A drug utilization cohort study based on data from the Norwegian prescription database","volume":"26","author":"G Raknes","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref12","unstructured":"Shiller AD. Healing Chronic Pain and Illness with LDN (Low Dose Naltrexone) Part 1. 16 August 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.drshiller.com\/healing-chronic-pain-illness-ldn-low-dose-naltrexone-part-1\/\" xlink:type=\"simple\">https:\/\/www.drshiller.com\/healing-chronic-pain-illness-ldn-low-dose-naltrexone-part-1\/<\/ext-link>. Cited 23 November 2018."},{"key":"ref13","first-page":"129","article-title":"Establishment of the nationwide Norwegian Prescription Database (NorPD)\u2013new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"K Furu","year":"2008","journal-title":"Nor J Epidemiol"},{"key":"ref14","unstructured":"Norwegian Institute of Public Health. Norwegian Prescription Database. 20 September 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.fhi.no\/en\/hn\/health-registries\/norpd\/norwegian-prescription-database\/\" xlink:type=\"simple\">https:\/\/www.fhi.no\/en\/hn\/health-registries\/norpd\/norwegian-prescription-database\/<\/ext-link>. Cited 23 November 2018."},{"key":"ref15","article-title":"ICPC-2: International Classification of Primary Care","year":"1998"},{"key":"ref16","first-page":"234","article-title":"Practical Statistics for Medical Research","author":"DG Altman","year":"1991"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2017.07.008","article-title":"Heterogeneity in application, design, and analysis characteristics was found for controlled before-after and interrupted time series studies included in Cochrane reviews","volume":"91","author":"S Polus","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/pds.4201","article-title":"Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database","volume":"26","author":"G Raknes","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"J Younger","year":"2009","journal-title":"Pain med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low\u2010dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double\u2010blind, placebo\u2010controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"J Younger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11926-016-0581-0","article-title":"Non-inflammatory Causes of Pain in Patients with Rheumatoid Arthritis","volume":"18","author":"SD Boyden","year":"2016","journal-title":"Curr Rheumatol Rep"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0223545","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0212460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T16:08:35Z","timestamp":1720973315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0212460"}},"subtitle":[],"editor":[{"given":"Domenico Paolo Emanuele","family":"Margiotta","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0212460","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]}}}